LGM
MAZE

Logos Global Management’s Maze Therapeutics MAZE Stock Holding History

Logos Global Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.7M Buy
1,935,000
+700,000
+57% +$18.3M 2.49% 13
2026
Q1 		$36.9M Buy
1,235,000
+285,000
+30% +$12.6M 1.84% 16
2025
Q4 		$39.4M Sell
950,000
-277,300
-23% -$9.53M 2.38% 12
2025
Q3 		$31.8M Buy
1,227,300
+615,386
+101% +$10.4M 2.85% 11
2025
Q2 		$7.51M Sell
611,914
-325,000
-35% -$3.38M 0.83% 36
2025
Q1 		$10.3M Buy
+936,914
New +$11.3M 1.83% 21

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Logos Global Management's MAZE Position: Q2 2026 in Review

Logos Global Management increased its Maze Therapeutics (MAZE) stake by 57% in Q2 2026, buying an estimated $18.3M and bringing the position to 1,935,000 shares worth $57.7M. The position accounts for 2.49% of the portfolio, ranked #13.

Logos Global Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Logos Global Management held 1,935,000 shares of Maze Therapeutics worth $57.7M as of Q2 2026.
  • Logos Global Management bought 700,000 Maze Therapeutics shares in Q2 2026, an estimated $18.3M.
  • Maze Therapeutics made up 2.49% of Logos Global Management's portfolio in Q2 2026, its #13 holding.
  • Logos Global Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.